{"id":67408,"date":"2026-06-05T13:38:43","date_gmt":"2026-06-05T05:38:43","guid":{"rendered":"https:\/\/flcube.com\/?p=67408"},"modified":"2026-06-05T13:38:44","modified_gmt":"2026-06-05T05:38:44","slug":"pfizer-licenses-chai-discoverys-ai-platform-for-drug-discovery-gains-early-access-to-breakthrough-chai-3-model-for-antibody-design","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67408","title":{"rendered":"Pfizer Licenses Chai Discovery&#8217;s AI Platform for Drug Discovery \u2013 Gains Early Access to Breakthrough Chai-3 Model for Antibody Design"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Pfizer<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) announced a strategic license agreement with <strong>Chai Discovery<\/strong>, an artificial intelligence company specializing in molecular design, granting Pfizer access to deploy <strong>Chai&#8217;s AI platform<\/strong> as part of its <strong>drug discovery engine<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-transaction-details\" class=\"wp-block-heading\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Pfizer (licensee) \/ Chai Discovery (licensor)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>04 Jun 2026<\/td><\/tr><tr><td><strong>Platform Access<\/strong><\/td><td>Chai&#8217;s generative AI drug discovery platform<\/td><\/tr><tr><td><strong>Key Assets<\/strong><\/td><td>Early access to <strong>Chai-3 model<\/strong> + <strong>custom model<\/strong> leveraging Pfizer&#8217;s proprietary data<\/td><\/tr><tr><td><strong>Customization<\/strong><\/td><td>Tailored integration with Pfizer&#8217;s existing drug discovery workflows<\/td><\/tr><tr><td><strong>Technology Focus<\/strong><\/td><td>AI-driven biomolecular design and antibody engineering<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-technology-profile-amp-innovation\" class=\"wp-block-heading\">Technology Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Capability:<\/strong> Generative AI software that can <strong>predict and reprogram molecular interactions<\/strong><\/li>\n\n\n\n<li><strong>Primary Application:<\/strong> Enables scientists to <strong>design biomolecules with specific functional properties<\/strong><\/li>\n\n\n\n<li><strong>Flagship Model:<\/strong> <strong>Chai-3<\/strong> \u2013 previously undisclosed next-generation AI model<\/li>\n\n\n\n<li><strong>Performance Metrics:<\/strong> <strong>Doubles the success rate<\/strong> of predecessor model in antibody design<\/li>\n\n\n\n<li><strong>Quality Standards:<\/strong> Produces antibodies that <strong>meet required therapeutic standards<\/strong><\/li>\n\n\n\n<li><strong>Strategic Integration:<\/strong> Custom model incorporates Pfizer&#8217;s proprietary data and aligns with established R&amp;D workflows<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-industry-impact\" class=\"wp-block-heading\">Competitive Landscape &amp; Industry Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Traditional Drug Discovery<\/th><th>Chai-Pfizer AI Integration<\/th><\/tr><\/thead><tbody><tr><td><strong>Timeline<\/strong><\/td><td>4-6 years from target identification to clinical candidate<\/td><\/tr><tr><td><strong>Success Rate<\/strong><\/td><td>&lt;10% of candidates advance beyond preclinical<\/td><\/tr><tr><td><strong>Resource Intensity<\/strong><\/td><td>High-throughput screening requiring extensive laboratory resources<\/td><\/tr><tr><td><strong>Innovation Risk<\/strong><\/td><td>Incremental improvements on known scaffolds<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pfizer&#8217;s AI Strategy:<\/strong> Represents significant expansion of Pfizer&#8217;s artificial intelligence capabilities in early-stage drug discovery<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Early access to Chai-3 provides potential first-mover advantage in AI-designed biologics<\/li>\n\n\n\n<li><strong>R&amp;D Productivity:<\/strong> Custom integration expected to enhance hit-to-lead conversion rates across multiple therapeutic areas<\/li>\n\n\n\n<li><strong>Financial Terms:<\/strong> Specific financial details undisclosed, but typical industry AI platform deals range from $50-200 million in upfront and milestone payments<\/li>\n\n\n\n<li><strong>Market Positioning:<\/strong> Positions Pfizer at forefront of AI-driven drug discovery alongside competitors like Roche, Novartis, and Merck<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding strategic partnerships, technology integration, and research productivity expectations. Actual results may differ due to risks including technical implementation challenges, competitive developments, and regulatory considerations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,863,309],"class_list":["post-67408","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ai","tag-nyse-pfe","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Licenses Chai Discovery&#039;s AI Platform for Drug Discovery \u2013 Gains Early Access to Breakthrough Chai-3 Model for Antibody Design - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company specializing in molecular design, granting Pfizer access to deploy Chai&#039;s AI platform as part of its drug discovery engine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67408\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Licenses Chai Discovery&#039;s AI Platform for Drug Discovery \u2013 Gains Early Access to Breakthrough Chai-3 Model for Antibody Design\" \/>\n<meta property=\"og:description\" content=\"Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company specializing in molecular design, granting Pfizer access to deploy Chai&#039;s AI platform as part of its drug discovery engine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67408\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T05:38:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T05:38:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67408#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67408\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Licenses Chai Discovery&#8217;s AI Platform for Drug Discovery \u2013 Gains Early Access to Breakthrough Chai-3 Model for Antibody Design\",\"datePublished\":\"2026-06-05T05:38:43+00:00\",\"dateModified\":\"2026-06-05T05:38:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67408\"},\"wordCount\":349,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67408#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67408\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67408\",\"name\":\"Pfizer Licenses Chai Discovery's AI Platform for Drug Discovery \u2013 Gains Early Access to Breakthrough Chai-3 Model for Antibody Design - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-05T05:38:43+00:00\",\"dateModified\":\"2026-06-05T05:38:44+00:00\",\"description\":\"Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company specializing in molecular design, granting Pfizer access to deploy Chai's AI platform as part of its drug discovery engine.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67408#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67408\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67408#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Licenses Chai Discovery&#8217;s AI Platform for Drug Discovery \u2013 Gains Early Access to Breakthrough Chai-3 Model for Antibody Design\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Licenses Chai Discovery's AI Platform for Drug Discovery \u2013 Gains Early Access to Breakthrough Chai-3 Model for Antibody Design - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company specializing in molecular design, granting Pfizer access to deploy Chai's AI platform as part of its drug discovery engine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67408","og_locale":"en_US","og_type":"article","og_title":"Pfizer Licenses Chai Discovery's AI Platform for Drug Discovery \u2013 Gains Early Access to Breakthrough Chai-3 Model for Antibody Design","og_description":"Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company specializing in molecular design, granting Pfizer access to deploy Chai's AI platform as part of its drug discovery engine.","og_url":"https:\/\/flcube.com\/?p=67408","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-05T05:38:43+00:00","article_modified_time":"2026-06-05T05:38:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67408#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67408"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Licenses Chai Discovery&#8217;s AI Platform for Drug Discovery \u2013 Gains Early Access to Breakthrough Chai-3 Model for Antibody Design","datePublished":"2026-06-05T05:38:43+00:00","dateModified":"2026-06-05T05:38:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67408"},"wordCount":349,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","NYSE: PFE","Pfizer"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67408#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67408","url":"https:\/\/flcube.com\/?p=67408","name":"Pfizer Licenses Chai Discovery's AI Platform for Drug Discovery \u2013 Gains Early Access to Breakthrough Chai-3 Model for Antibody Design - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-05T05:38:43+00:00","dateModified":"2026-06-05T05:38:44+00:00","description":"Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company specializing in molecular design, granting Pfizer access to deploy Chai's AI platform as part of its drug discovery engine.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67408#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67408"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67408#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Licenses Chai Discovery&#8217;s AI Platform for Drug Discovery \u2013 Gains Early Access to Breakthrough Chai-3 Model for Antibody Design"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67408"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67408\/revisions"}],"predecessor-version":[{"id":67413,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67408\/revisions\/67413"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}